Thymidylate Synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1534-1539

  Righi, Luisella ^a   Papotti, Mauro G ^a   Ceppi, Paolo ^a   Billè, Andrea ^a   Bacillo, Elisa ^a   Molinaro, Luca ^a   Ruffini, Enrico ^a   Scagliotti, Giorgio V ^a   Selvaggi, Giovanni ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; HELICASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; FEMALE; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BIOSYNTHESIS; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PLEURA TUMOR; PREDICTION AND FORECASTING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; DNA HELICASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 77951894575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.9275     Document Type: Article

References (32)

1. Treasure T, Sedrakyan A: Pleural mesothelioma: Little evidence, still time to do trials. Lancet 364:1183-1185, 2004
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003 (Pubitemid 46606305)
3. Janne PA, Wozniak AJ, Belani CP, et al: Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program. J Thorac Oncol 1:506-512, 2006 (Pubitemid 47181396)
4. Santoro A, O'Brien ME, Stahel RA, et al: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol 3:756-763, 2008
5. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997 (Pubitemid 27138611)
6. Giovannetti E, Backus HH, Wouters D, et al: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 96:769-775, 2007 (Pubitemid 46376640)
7. Gomez HL, Santillana SL, Vallejos CS, et al: A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression. Clin Cancer Res 12:832-838, 2006 (Pubitemid 43259865)
8. Rose MG, Farrell MP, Schmitz JC: Thymidylate synthase: A critical target for cancer chemotherapy. Clin Colorectal Cancer 1:220-229, 2002 (Pubitemid 34269382)
9. Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107:1589-1596, 2006 (Pubitemid 44546920)
10. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 14:253-263, 2009
11. Belani CP, Brodowicz T, Ciuleanu T, et al: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27:15S, 2009 (suppl; abstr CRA8000)
12. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
13. Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22-33, 2001
14. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747-2754, 2007 (Pubitemid 47123183)
15. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006 (Pubitemid 44343542)
16. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007 (Pubitemid 46294612)
17. Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731-4737, 2006 (Pubitemid 46646245)
18. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818-1825, 2006
19. Holm B, Mellemgaard A, Skov T, et al: Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27:4254-4259, 2008
20. Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients: Part 2: Prognosis and staging. Cancer 72:394-404, 1993 (Pubitemid 23193444)
21. Borasio P, Berruti A, Bille A, et al: Malignant pleural mesothelioma: Clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 33:307-313, 2008
22. Maggi G, Casadio C, Cianci R, et al: Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 19:346-350, 2001 (Pubitemid 32197443)
23. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6:986-994, 1996 (Pubitemid 26388091)
24. Cappia S, Righi L, Mirabelli D, et al: Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 130:58-64, 2008
25. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577, 1993 (Pubitemid 23118304)
26. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36, 1982 (Pubitemid 12142173)
27. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma: From the International Mesothelioma Interest Group. Chest 108:1122-1128, 1995
28. Francart J, Legrand C, Sylvester R, et al: Progression-free survival rate as primary end point for phase II cancer clinical trials: Application to mesothelioma-The EORTC Lung Cancer Group. J Clin Oncol 24:3007-3012, 2006 (Pubitemid 46638933)
29. Zheng Z, Li X, Schell MJ, et al: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 112:2765-2773, 2008 (Pubitemid 351969222)
30. Scagliotti GV, Monica V, Ceppi P, et al: Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol 27:15S, 2009 (suppl; abstr 7521)
31. Ceppi P, Volante M, Ferrero A, et al: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14:1059-1064, 2008 (Pubitemid 351302551)
32. Jalal S, Ansari R, Govindan R, et al: Pemetrexed in second line and beyond small cell lung cancer: A Hoosier Oncology Group phase II study. J Thorac Oncol 4:93-96, 2009